Abidor versus ritonavir in the treatment of Covid-19
阿比多尔与利托那韦治疗新冠肺炎的对比研究

摘要

目的 研究阿比多尔和利托那韦在新冠肺炎治疗中的对比。方法 将我院治疗的新冠肺炎患者作为案例，从中选出300例按照不同治疗进行分组，每组150例，对照组采用的是阿比多尔药物，观察组则是利托那韦药物治疗，对比两组治疗效果和不良反应发生率。结果 在效果以及不良反应发生率对比结果中发现，观察组明显效果提高，对比有差异（P＜0.05），其不良反应发生概率较低，并未产生差异性（P＞0.05）。结论 两种不同药物治疗新冠肺炎疾病，明显发现利托那韦治疗效果得到提升，不良反应发生率较低，因此临床可对利托那韦药物进行深入研究和推广。

Abstract

Objective To study the comparison of arbidol and Ritonavir in the treatment of COVID-19.
Methods 300 patients treated with COVID-19 in our hospital were selected as cases and divided into groups according to different treatments, with 150 cases in each group. The control group was treated with arbidol and the observation group was treated with ritonavir. The therapeutic effect and incidence of adverse reactions were compared between the two groups.
Results In the comparison results of effect and incidence of adverse reactions, it was found that the effect was significantly improved in the observation group (P < 0.05), and the probability of adverse reactions was lower, and there was no difference (P > 0.05).
Conclusion   In the treatment of novel coronavirus pneumonia by two different drugs, it was obviously found that the therapeutic effect of ritonavir was improved and the incidence of adverse reactions was low. Therefore, Ritonavir can be further studied and promoted in clinic.